These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 27039923)

  • 21. Drug ratio-dependent antagonism: a new category of multidrug resistance and strategies for its circumvention.
    Harasym TO; Liboiron BD; Mayer LD
    Methods Mol Biol; 2010; 596():291-323. PubMed ID: 19949929
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Methods of overcoming treatment resistance in colorectal cancer.
    Temraz S; Mukherji D; Alameddine R; Shamseddine A
    Crit Rev Oncol Hematol; 2014 Feb; 89(2):217-30. PubMed ID: 24075059
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rational combination therapy of vintafolide (EC145) with commonly used chemotherapeutic drugs.
    Reddy JA; Dorton R; Bloomfield A; Nelson M; Vetzel M; Guan J; Leamon CP
    Clin Cancer Res; 2014 Apr; 20(8):2104-14. PubMed ID: 24429878
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Calculated resistance in cancer.
    Sawyers CL
    Nat Med; 2005 Aug; 11(8):824-5. PubMed ID: 16079872
    [No Abstract]   [Full Text] [Related]  

  • 25. Review of the contemporary cytotoxic and biologic combinations available for the treatment of metastatic breast cancer.
    Tkaczuk KH
    Clin Ther; 2009; 31 Pt 2():2273-89. PubMed ID: 20110041
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeted therapy in cancer.
    Tsimberidou AM
    Cancer Chemother Pharmacol; 2015 Dec; 76(6):1113-32. PubMed ID: 26391154
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.
    Camicia R; Winkler HC; Hassa PO
    Mol Cancer; 2015 Dec; 14():207. PubMed ID: 26654227
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Platinum compounds in the treatment of advanced breast cancer.
    Martín M
    Clin Breast Cancer; 2001 Oct; 2(3):190-208; discussion 209. PubMed ID: 11899413
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rational combinations using HDAC inhibitors.
    Bots M; Johnstone RW
    Clin Cancer Res; 2009 Jun; 15(12):3970-7. PubMed ID: 19509171
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Microtubule stabilising agents for cancer chemotherapy.
    Zhao Y; Fang WS; Pors K
    Expert Opin Ther Pat; 2009 May; 19(5):607-22. PubMed ID: 19441937
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epigenetic targeting therapies to overcome chemotherapy resistance.
    Balch C; Nephew KP
    Adv Exp Med Biol; 2013; 754():285-311. PubMed ID: 22956507
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Disrupting cancer cells' biocircuits with interactome-based drugs: is 'clinical' innovation realistic?
    Roukos DH
    Expert Rev Proteomics; 2012 Aug; 9(4):349-53. PubMed ID: 22967071
    [No Abstract]   [Full Text] [Related]  

  • 34. Metronomic reloaded: Theoretical models bringing chemotherapy into the era of precision medicine.
    Benzekry S; Pasquier E; Barbolosi D; Lacarelle B; Barlési F; André N; Ciccolini J
    Semin Cancer Biol; 2015 Dec; 35():53-61. PubMed ID: 26361213
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular-targeted agents combination therapy for cancer: developments and potentials.
    Li F; Zhao C; Wang L
    Int J Cancer; 2014 Mar; 134(6):1257-69. PubMed ID: 23649791
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Heat-Shock Protein 90-Targeted Nano Anticancer Therapy.
    Rochani AK; Ravindran Girija A; Borah A; Maekawa T; Sakthi Kumar D
    J Pharm Sci; 2016 Apr; 105(4):1454-66. PubMed ID: 26886301
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multifunctional and multitargeted nanoparticles for drug delivery to overcome barriers of drug resistance in human cancers.
    Dawar S; Singh N; Kanwar RK; Kennedy RL; Veedu RN; Zhou SF; Krishnakumar S; Hazra S; Sasidharan S; Duan W; Kanwar JR
    Drug Discov Today; 2013 Dec; 18(23-24):1292-300. PubMed ID: 24055842
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Personalized medicine in oncology: a personal view with myths and facts.
    Beijnen JH; Schellens JH
    Curr Clin Pharmacol; 2010 Aug; 5(3):141-7. PubMed ID: 20406176
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emerging role of pemetrexed in ovarian cancer.
    Tomao F; Panici PB; Frati L; Tomao S
    Expert Rev Anticancer Ther; 2009 Dec; 9(12):1727-35. PubMed ID: 19954283
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeted therapy for advanced prostate cancer: Looking through new lenses.
    Vogiatzi P; Cassone M; Claudio L; Claudio PP
    Drug News Perspect; 2009 Dec; 22(10):593-601. PubMed ID: 20140279
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.